Prognostic Impact of FDG-PET in Surgically Treated Pathological Stage I Lung Adenocarcinoma

被引:7
作者
Higuchi, Mitsunori [1 ]
Hasegawa, Takeo [1 ]
Osugi, Jun [1 ]
Suzuki, Hiroyuki [1 ]
Gotoh, Mitsukazu [1 ]
机构
[1] Fukushima Med Univ, Sch Med, Dept Thorac Surg, Fukushima 9601295, Japan
关键词
18F-deoxyglucose-positron emission tomography; maximum standardized uptake value; pathological stage I lung adenocarcinoma; prognostic factor; lymphovascular involvement; POSITRON-EMISSION-TOMOGRAPHY; STANDARDIZED UPTAKE VALUE; 2ND EDITION; CANCER; SURVIVAL; RECURRENCE;
D O I
10.5761/atcs.oa.12.02219
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Purpose: This retrospective study evaluated whether the maximum standardized uptake value (SUVmax) on 18F-deoxyglucose (FDG)-positron emission tomography (PET) could be used to predict the prognosis of patients with pathological stage I adenocarcinoma. Methods: We analyzed 138 consecutive patients with pathological stage IA or IB lung adenocarcinoma except pure bronchioloalveolar carcinoma (BAC) who underwent pre-operative FDG-PET imaging and curative resection from January 2005 to October 2010. We analyzed associations between disease-free survival (DFS) and clinicopathological factors. Results: The 5-year DFS rate was 77.7%. Twenty two patients (15.9%) developed recurrence after surgery. Multivariate analysis identified SUVmax and lymphovascular (ly) involvement as the independent prognostic factors for recurrence (p = 0.0255 and p = 0.0333, respectively). We divided the patients into groups according to SUVmax and ly involvement. The 5-year DFS rate was 97.0% in patients with SUVmax <= 2.5 and without ly involvement, 100% with both SUVmax <= 2.5 and ly involvement, 70.2% with SUVmax >2.5 and without ly involvement, and 53.1% with both SUVmax >2.5 and ly involvement. Conclusions: The results of this study suggest that SUVmax and ly involvement could be used to predict the prognosis of patients with pathological stage I adenocarcinoma. The combination of these prognostic factors could also identify high risk groups of recurrence.
引用
收藏
页码:185 / 191
页数:7
相关论文
共 15 条
  • [11] Prognostic significance of [18F]fluorodeoxyglucose uptake on positron emission tomography in patients with pathologic stage I lung adenocarcinoma
    Ohtsuka, Takashi
    Nomori, Hiroaki
    Watanabe, Ken-ichi
    Kaji, Masahiro
    Naruke, Tsuguo
    Suemasu, Keiichi
    Uno, Kimiichi
    [J]. CANCER, 2006, 107 (10) : 2468 - 2473
  • [12] Primary Tumor Standardized Uptake Value Measured on Fluorodeoxyglucose Positron Emission Tomography Is of Prognostic Value for Survival in Non-small Cell Lung Cancer Update of a Systematic Review and Meta-Analysis by the European Lung Cancer Working Party for the International Association for the Study of Lung Cancer Staging Project
    Paesmans, Marianne
    Berghmans, Thierry
    Dusart, Michele
    Garcia, Camillo
    Hossein-Foucher, Claude
    Lafitte, Jean-Jacques
    Mascaux, Celine
    Meert, Anne-Pascale
    Roelandts, Martine
    Scherpereel, Arnaud
    Munoz, Vanessa Terrones
    Sculier, Jean-Paul
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2010, 5 (05) : 612 - 619
  • [13] Follow-up and surveillance of the lung cancer patient following curative intent therapy - ACCP evidence-based clinical practice guideline (2nd edition)
    Rubins, Jeffrey
    Unger, Michael
    Colice, Gene L.
    [J]. CHEST, 2007, 132 (03) : 355S - 367S
  • [14] Positron emission tomography for predicting recurrence in stage I lung adenocarcinoma: standardized uptake value corrected by mean liver standardized uptake value
    Shiono, Satoshi
    Abiko, Masami
    Okazaki, Toshimasa
    Chiba, Masato
    Yabuki, Hiroshi
    Sato, Toru
    [J]. EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY, 2011, 40 (05) : 1165 - 1169
  • [15] Relationship between non-small cell lung cancer FDG uptake at PET, tumor histology, and Ki-67 proliferation index
    Vesselle, Hubert
    Salskov, Alexander
    Turcotte, Eric
    Wiens, Linda
    Schmidt, Rodney
    Jordan, Diana
    Vallieres, Eric
    Wood, Douglas E.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2008, 3 (09) : 971 - 978